Mounjaro for Sleep Apnea: Off-Label Use, Dosing Protocol, and Clinical Evidence

Why Tirzepatide Is Being Studied for Sleep Apnea

Obstructive sleep apnea and obesity share a tight bidirectional relationship. Excess adipose tissue around the pharynx narrows the upper airway, and OSA itself promotes metabolic dysfunction that makes weight loss harder. An estimated 60 to 90% of adults with moderate-to-severe OSA also carry a BMI ≥30 1. CPAP remains first-line therapy, but adherence rates hover near 50% at 12 months 2.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produced the largest weight reductions of any approved anti-obesity medication in the SURMOUNT program. Because pharyngeal fat mass correlates directly with AHI, clinicians reasoned that aggressive weight loss could reduce or resolve OSA pathology at its mechanical root 3. That hypothesis drove the design of SURMOUNT-OSA.

The drug is FDA-approved for type 2 diabetes under the Mounjaro brand and for chronic weight management under the Zepbound brand. Any prescription of Mounjaro specifically for OSA is off-label. Zepbound does not yet carry an OSA indication either, though Eli Lilly has pursued one.

SURMOUNT-OSA Trial: Design and Key Results

The SURMOUNT-OSA program consisted of two parallel, randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in June 2024 4. Study 1 enrolled 234 participants with moderate-to-severe OSA (AHI ≥15) who were not using PAP therapy. Study 2 enrolled 235 participants who were on stable PAP therapy. All participants had a BMI ≥30.

Patients received subcutaneous tirzepatide escalated to the maximum tolerated dose (10 mg or 15 mg weekly) or placebo for 52 weeks. The primary endpoint was change in AHI from baseline to week 52 as measured by polysomnography.

The results were striking. In Study 1, tirzepatide reduced AHI by a mean of 25.3 events per hour compared to 5.3 for placebo (treatment difference: −20.0; 95% CI, −25.8 to −14.2) 4. In Study 2, the AHI reduction was 29.3 events per hour with tirzepatide versus 5.5 with placebo (treatment difference: −23.8; 95% CI, −29.6 to −18.0) 4. Body weight decreased by approximately 18% in Study 1 and 20% in Study 2.

Disease resolution (AHI <5 events per hour) occurred in 42% of tirzepatide-treated participants in Study 1 and 51% in Study 2, compared with 14% and 16% in the respective placebo groups 4.

Dr. Atul Malhotra, principal investigator of the SURMOUNT-OSA trial and professor of medicine at UC San Diego, stated: "These results suggest that treating obesity can profoundly improve obstructive sleep apnea, and for some patients, potentially resolve it entirely" 4.

Off-Label Dosing Protocol

The dosing protocol used in SURMOUNT-OSA mirrors the standard tirzepatide titration for weight management. No OSA-specific dosing schedule exists.

Week 1, 4: 2.5 mg subcutaneous injection once weekly. This is a tolerability dose, not a therapeutic dose.

Week 5, 8: 5 mg once weekly. GI side effects (nausea, diarrhea, constipation) are most common during early escalation.

Week 9, 12: 7.5 mg once weekly.

Week 13, 16: 10 mg once weekly. Many patients in SURMOUNT-OSA reached maximum tolerated dose at this level.

Week 17, 20: 12.5 mg once weekly.

Week 21 onward: 15 mg once weekly, if tolerated.

The trial allowed investigators to hold dose escalation or reduce the dose by one step for tolerability. In practice, clinicians should titrate based on GI tolerability and clinical response, reassessing AHI via home sleep testing or polysomnography at 6 and 12 months 5.

One point deserves emphasis. The SURMOUNT-OSA outcomes were achieved at the 10 mg and 15 mg doses, not lower maintenance doses. Patients who plateau at 5 mg or 7.5 mg due to side effects may not achieve the same AHI reductions observed in the trial.

How Weight Loss Improves AHI: The Mechanism

A 10% reduction in body weight predicts an approximate 26% reduction in AHI, based on data from the Wisconsin Sleep Cohort 6. The mechanism is anatomical. Pharyngeal fat deposits compress the lateral walls of the upper airway, and visceral adiposity increases abdominal pressure, reducing lung volume and tracheal tug. Losing weight reverses both effects.

Tirzepatide's dual GIP/GLP-1 receptor agonism produces weight loss through reduced appetite, delayed gastric emptying, and improved central satiety signaling. The 18 to 20% body weight reduction seen in SURMOUNT-OSA exceeds the threshold where clinically meaningful AHI improvements become likely. CT imaging studies have shown that even modest fat loss in the parapharyngeal space widens the retropalatal airway by 1 to 3 mm, a change that dramatically alters airflow dynamics during sleep 3.

GLP-1 receptor agonists may also reduce OSA severity through weight-independent pathways, including reduced systemic inflammation (lower CRP, TNF-alpha, IL-6) and improved ventilatory drive. These effects have been observed with liraglutide and semaglutide, though they remain less well characterized for tirzepatide specifically 7.

Comparing Tirzepatide to Other OSA Interventions

CPAP therapy typically reduces AHI by 25, 30 events per hour in moderate-to-severe OSA 2. Tirzepatide's mean AHI reduction of 25, 30 events per hour in SURMOUNT-OSA is comparable in magnitude, though the comparison is indirect and these treatments work through entirely different mechanisms.

Semaglutide has also been studied for OSA. The STEP-OSA trial is investigating semaglutide 2.4 mg for this indication. An earlier analysis of STEP-1 subgroup data suggested AHI reductions of approximately 8, 10 events per hour with semaglutide 2.4 mg and roughly 16% body weight loss 8. Tirzepatide appears to offer larger AHI reductions, consistent with its greater weight loss efficacy.

Surgical weight loss (bariatric surgery) reduces AHI by roughly 30, 40 events per hour in meta-analyses, but carries operative risk and is irreversible 9. The American Academy of Sleep Medicine (AASM) 2023 guidelines recognize weight management as an adjunctive therapy for OSA but do not yet endorse any specific anti-obesity medication for this purpose 10.

Dr. Sanjay Patel, director of the Center for Sleep and Cardiovascular Outcomes Research at the University of Pittsburgh, has noted: "We may be entering an era where pharmacologic weight loss becomes a pillar of sleep apnea management alongside PAP and oral appliances, rather than a secondary recommendation" 4.

Risks, Limitations, and What Is Not Yet Known

Tirzepatide's safety profile in SURMOUNT-OSA was consistent with prior weight management trials. The most common adverse events were gastrointestinal: nausea (24 to 33%), diarrhea (16 to 22%), and constipation (10 to 14%) 4. Treatment discontinuation due to adverse events occurred in approximately 5 to 7% of tirzepatide-treated participants.

Several limitations deserve attention.

The trial duration was 52 weeks. Long-term durability of AHI reductions is unknown. Weight regain after GLP-1 RA discontinuation is well documented (the SURMOUNT-4 extension study showed two-thirds of lost weight returned within 52 weeks of stopping tirzepatide) 11, and AHI would be expected to worsen in parallel.

SURMOUNT-OSA excluded patients with BMI <30, central sleep apnea, significant craniofacial abnormalities, and those with severe hypoxemia requiring urgent intervention. The results should not be extrapolated to lean OSA patients or those with non-obesity-related airway obstruction.

Cost is a barrier. A monthly supply of tirzepatide runs $1,000, $1,100 without insurance. Most payers do not cover GLP-1 receptor agonists for an OSA indication. Off-label prescribing complicates reimbursement 12.

Pancreatitis risk, though rare (incidence <0.5% in clinical trials), warrants monitoring with lipase levels if symptoms arise 5. The FDA requires a boxed warning about medullary thyroid carcinoma risk based on rodent studies, though no confirmed human cases have been attributed to tirzepatide.

Who Might Be a Candidate for Off-Label Prescribing

A reasonable clinical profile for off-label tirzepatide in OSA includes patients who meet all of the following criteria: BMI ≥30, moderate-to-severe OSA (AHI ≥15), documented CPAP intolerance or non-adherence, and no contraindications to GLP-1 receptor agonists (history of pancreatitis, personal or family history of medullary thyroid carcinoma, MEN2 syndrome).

Patients with concurrent type 2 diabetes represent the simplest prescribing scenario because tirzepatide is already FDA-approved for that indication. Prescribing Mounjaro for diabetes in a patient who also has OSA is on-label, with the AHI benefit as a secondary outcome.

For patients without diabetes, prescribers should document the off-label rationale, cite the SURMOUNT-OSA evidence, obtain informed consent noting the off-label status, and arrange follow-up polysomnography at 6 and 12 months to quantify response 10. Baseline and periodic monitoring of HbA1c, lipase, and renal function is standard practice.

The Endocrine Society's 2023 clinical practice guideline on pharmacotherapy for obesity recommends tirzepatide as a first-line pharmacologic option for patients with BMI ≥30 (or ≥27 with weight-related comorbidities), which would include obesity-related OSA 13.

Regulatory Status and What Comes Next

Eli Lilly submitted data from SURMOUNT-OSA to the FDA in late 2024 to support a supplemental indication for tirzepatide (under the Zepbound brand) in moderate-to-severe OSA. An FDA decision was expected in early 2025. If approved, Zepbound would become the first pharmaceutical therapy specifically indicated for obstructive sleep apnea 14.

The clinical community is also watching for longer-duration extension data. Whether patients can maintain AHI reductions beyond 52 weeks while on therapy, and what happens to AHI after drug discontinuation, will determine how tirzepatide fits into long-term OSA management algorithms.

A polysomnography-confirmed AHI <5 at 12 months, combined with resolution of daytime sleepiness (Epworth Sleepiness Scale ≤10), would represent the strongest evidence for a trial off CPAP in tirzepatide-treated patients. That protocol has not been validated in prospective studies. Until it is, most sleep medicine specialists will recommend continuing PAP therapy even in patients whose AHI drops below the diagnostic threshold on tirzepatide.